This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Curis Reports CUDC-907 And CUDC-427 Data At AACR Annual Meeting 2014

CUDC-907 Modulates Expression of Certain Cytokines/ Chemokines, Potentially Targeting Tumor Microenvironment in Addition to Direct Effects on Cancer Cells

Sensitivity to CUDC-427 May Be Predicted by Alterations in TNF-α and XIAP Expression

LEXINGTON, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that it reported data from in vitro studies and a translational biomarker analysis for CUDC-907, a dual histone deacytelase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor, as well as results from in vitro and in vivo studies for CUDC-427, an antagonist of inhibitor of apoptosis (IAP) proteins, at the American Association for Cancer Research (AACR) 2014 Annual Meeting. CUDC-907 is being investigated in a Phase 1 trial in patients with relapsed/refractory lymphoma or multiple myeloma. CUDC-427 is being studied in a Phase 1 trial in patients with advanced solid tumors or lymphoma.

CUDC-907 Presentation

Curis scientists presented an abstract entitled " Dual function HDAC and PI3K inhibitor, CUDC-907 affects cancer cells and the tumor microenvironment in hematological malignancies" on Monday, April 7, 2014.The poster presentation included data from cell-based hematologic models suggesting that, in addition to direct effects on cancer cells, CUDC-907 may also alter the tumor microenvironment as measured by changes in the levels of certain cytokines and chemokines. Exposure of Hodgkin's lymphoma, diffuse large B-cell lymphoma and multiple myeloma cell lines to CUDC-907 resulted in reduction in the levels of CCL17 (TARC), a chemokine involved in the stimulation and proliferation of helper T cells required for the survival of certain malignant blood cells.

Preliminary data from patients with lymphoma treated with CUDC-907 in the ongoing Phase 1 study suggested correlative trends between patient benefit and plasma TARC levels prior to treatment, as well as potential correlations between tumor response and plasma TARC level changes induced by 15 days of CUDC-907 treatment. Further analysis of plasma cytokine and chemokine levels is ongoing to explore TARC and other molecules as markers/predictors of CUDC-907's activity, which may also inform patient stratification strategies.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs